Rituximab Added to Treat Refractory Retroperitoneal Fibrosis Case
A case report describes the successful use of rituximab to treat refractory MPO-ANCA-positive retroperitoneal fibrosis after initial therapy failed.
A case report describes the successful use of rituximab to treat refractory MPO-ANCA-positive retroperitoneal fibrosis after initial therapy failed.
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.